P38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations

Abstract

COPD represents a major respiratory disorder, causing significant morbidity and mortality throughout the world. While therapies exist for COPD, they are not always effective, and many patients experience exacerbations and morbidity despite current therapies. Study of the molecular mechanisms involved in the underlying physiological manifestations of COPD has yielded multiple new targets for therapeutic intervention. In this review, we discuss signaling pathways involved in COPD pathogenesis and review clinical studies of p38 MAPK inhibitors, TNFα inhibitors, and IKK2 inhibitors as potential COPD therapies.

Original languageEnglish (US)
Pages (from-to)287-292
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume12
Issue number3
DOIs
StatePublished - Jun 2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'P38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD'. Together they form a unique fingerprint.

Cite this